US regulator observations at Baddi unit may not effect Cadila

Observations are related to Pre-Approval Inspection and the product is yet to be manufactured

Ahmedabad-headquartered Cadila Healthcare has today informed the Bombay Stock Exchange (BSE) that its Baddi plant has received three observations from the US Food and Drug Administration (USFDA) related to a pre-approval inspection (PAI) for a specific product filed. While the company's shares on the BSE tanked 1.76 per cent in day's trade, analysts say this would have no immediate impact on revenues.

Cadila Healthcare said in its statement that the USFDA had inspected its formulations manufacturing facility at Baddi from February 20 to March 1 and at the end of the inspection, there were three observations given under Form 483. "All